

CURRICULUM VITAE

Name: Irene Torresan

Date of birth: 21-09-1993

Place of Birth: Treviso, Italy

Citizenship: Italian

Italian Medical Council registration number: 6332, OMCEO Treviso

Email: irene.torresan@irst.emr.it

Current position

- 04 May 2026 – ongoing: Medical Oncologist, IRST IRCCS “Dino Amadori”, Meldola, Italy

Work experience

- 04 May 2026 – ongoing: Medical Oncologist, IRST IRCCS “Dino Amadori”, Meldola, Italy
- 01 December 2020 – 01 March 2021: Primary Care Doctor, ULSS2 Oderzo, Italy

Professional registration

- August 26, 2020: member of General Medical Council of Treviso (Italy), reference number 6332

Medical Training

- 05 May 2025 – 22 February 2026: Medical Oncology Residency, extra-University period at IRST IRCCS “Dino Amadori”, Meldola, Italy – Scientific Director Dr Nicola Normanno
- 01 August 2022 – 30 October 2022: Medical Oncology Residency, extra-University period in Unit of Medical Oncology, Vicenza Hospital, Italy – Director Dr Giuseppe Aprile
- 23 February 2021 – 22 February 2026: Medical Oncology Residency, University of Verona, Italy – Director Prof Michele Milella/Prof.ssa Sara Pilotto
- 04 March 2019 – 11 December 2019: traineeship as Medical Student – Laboratory of Human Immunology – Immunology and Molecular Unit of IOV-IRCCS Padova, Italy – Scientific Director Prof Alberto Amadori

Education and Training

- February 25, 2026: Postgraduate Specialization in Medical Oncology– University of Verona, Italy (final grade 70/70 cum Laude). Thesis: “Clinical and molecular study of patients with muscle-invasive bladder cancer undergoing neoadjuvant therapy: identification of biomarkers of response, resistance, and treatment failure.”
- June 17, 2025: ICH E6 R3-GCP training
- September 14, 2024: Achievement of ESMO Examination in Medical Oncology - Barcelona, Spain (This ESMO Examination certificate demonstrates that the applicant has successfully fulfilled the criteria of the European Society for Medical Oncology for excellent knowledge in this field of expertise).

- May 14, 2024: ICH-GCP training
- March 15-16, 2024: ALS training (Advanced Life Support), AOUI Verona
- May 13, 2022: ICH-GCP training
- July 22, 2020: Italian Medical License Exam (IMLE) – University of Padova, Italy
- December 13, 2019: Master Degree in Medicine and Surgery – University of Padova, Italy (final grade 110/110 cum Laude). Experimental thesis: “Determination of immunosuppressive activity of immune infiltrate and visualization of microenvironment in gliomas.”
- July 3, 2012: High School Diploma in Scientific Studies – Liceo Scientifico “Leonardo Da Vinci”, Treviso, Italy (100/100)

Clinical Research Activities

- 2026 Sub-investigator: MEVPRO-3 A phase 3 randomized double blind placebo controlled study of Mevrometostat (PF-06821497) with Enzalutamide in metastatic castration sensitive prostate cancer (NCT07028853).
- 2026 Sub-investigator: MEVPRO-2 A Phase 3, randomized, double-blind, placebo-controlled study of Mevrometostat (PF-06821497) plus Enzalutamide in metastatic castration-resistant prostate cancer (NCT06629779).
- 2026 Sub-investigator: MEVPRO-1 A multicenter, randomized, open-label, Phase 3 trial comparing the efficacy and safety of Mevrometostat (PF-06821497) plus Enzalutamide versus Enzalutamide or Docetaxel monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) following Abiraterone Acetate treatment (NCT06551324).
- 2026 Sub-investigator: Talapro-3 A Phase 3, randomized, double-blind, placebo-controlled study of Talazoparib with Enzalutamide in men with DDR-mutated metastatic castration-sensitive prostate cancer (NCT04821622).
- 2026 Sub-investigator: Talapro-2 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (NCT03395197).
- 2026 Sub-investigator: MCLA-158-CL03 A Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (NCT06525220).
- 2026 Sub-investigator: An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study (EudraCT N. 2020-005393-10).
- 2026 Sub-investigator: ASPEN Asymptomatic Small Pancreatic Endocrine Neoplasms (NCT03084770).
- 2025-2026 Sub-investigator: 20590 DAROL: Darolutamide observational study in non-metastatic castration resistant prostate cancer patients (NCT04122976).
- 2024-2025 Sub-Investigator: MOSAIC Exploiting heterogeneity in hormone response to reveal early determinants of drug resistance in advanced prostate cancers (NCT07352748).

- 2024-2025 Sub-Investigator: SGNDV-D001 An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater) (NCT05911295).
- 2024-2025 Sub-investigator: XL092-304 (STELLAR-304) A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (NCT05678673).
- 2024-2025 Sub-investigator: AVePEm An Observational Multicenter Retro-Pro prospective Study on Avelumab maintenance or second-line Pembrolizumab in patients affected by Advanced Urothelial Cancer, responsive to first-line platinum-based chemotherapy (NCT07207928).
- 2024-2025 Sub-investigator: IMMU-132-06 A phase II open-label study of Sacituzumab govitecan in unresectable locally advanced/metastatic urothelial cancer (NCT03547973).
- 2024-2025 Sub-investigator: D910PC00001 (VOLGA) A phase III randomized, open-label, multicenter study to determine the efficacy and safety of Durvalumab in combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in combination with Enfortumab Vedotin for perioperative treatment in patients ineligible for Cisplatin or who refuse Cisplatin undergoing radical cystectomy for muscle invasive bladder cancer (NCT04960709).
- 2024-2025 Sub-investigator: LCB-1801-001 A phase 1, open-label, dose finding study of NI-1801, a bispecific mesothelin x CD47 engaging antibody, as a single agent and in combination with anti-PD-1 antibody, in patients with mesothelin expressing solid cancers (NCT05403554).
- 2024 Sub-investigator: INCA 32459-101 A phase 1, open-label, multicenter study of INCA32459 in participants with select advanced malignancies (NCT05577182).
- 2023-2024 Sub-investigator: MO43989 An international prospective study to evaluate the impact of liquid biopsy in participants with a clinical diagnosis of advanced cancer (L1ST) (NCT05846594).
- 2023-2024 Sub-investigator: HBI-8000-303 Multicenter, Randomised, Double-Blind Phase 3 study of HBI-8000 combined with Nivolumab versus Placebo with Nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 (NCT04674683).
- 2023-2024 Sub-investigator: MK6482-015 (Litespark-015) A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2 α related Genetic Alterations (NCT04924075).
- 2022-2024 Sub-investigator: HS-19-657 (SORENTO) A randomised, multi-center, open-label, active-controlled phase 3 trial to assess the efficacy and safety of octreotide subcutaneous depot (CAM2029) versus octreotide LAR or Lanreotide ATG in patient with gastroenteropancreatic neuroendocrine tumors (NCT05050942).

Publications

<https://orcid.org/0009-0001-6578-4390>

- Rossi A, Borghesani M, Luchini C, Mafficini A, Cingarlini S, Landoni L, Benini L, Moscarda V, Reni A, Trevisani E, **Torresan I**, De Robertis R, D'Onofrio M, Salgarello M, Scarpa A, Milella M. Adult-onset metastatic pancreatic ganglioneuroblastoma with ALK gain-of-function mutation P.R1275Q treated with Lorlatinib. *Journal of Clinical Studies and Medical Case Reports*, **2023**, 10. DOI 10.24966/CSMC-8801/1000150.
- Trevisani E, Borghesani M, Reni A, **Torresan I**, Rossi A, Nicolini S, Milella M, Mazzaferri F, Ferrarini I, Parisi A, Cingarlini S. Unusual Presentation for EBV and HHV8 Co-Infections: A Case Report and Review of Literature. *Journal of Clinical Case Studies Reviews & Reports*, **2023**, 5 (9). DOI doi.org/10.47363/JCCSR/2023(5)258
- Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, **Torresan I**, Taymeh A, Filoni E, Luchini C, De Robertis R, Landoni L, Scarpa A, Porta C, Milella M, Strosberg J, Cives M, Cingarlini S. Efficacy and toxicity analysis of mFOLFIRINOX in high-grade gastroenteropancreatic neuroendocrine neoplasm. *J Natl Compr Canc Netw*. **2024** May 14:1-8. DOI:10.6004/jnccn.2024.7005.
- Zacchi F, Sordo A, **Torresan I**, Lorenzi C, Tasselli E, Pafumi S, Palmerio S, Durante E, Inzerilli N, Pellicciari M, Pastorelli D, Milella M, Lorenzoni G, Merler S and Zivi A (**2025**) Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVEPEM study). *Front. Oncol.* 15:1532421. doi: 10.3389/fonc.2025.1532421
- Francesca Zacchi, Sara Merler, Ilaria Zampiva, **Irene Torresan**, Stefano Manduca, Michela Piacentini, Clara Lorenzi, Emanuela Fantinel, Sarah Pafumi, Nicola Inzerilli, Anna Calì, Matteo Brunelli, Alessandro Veccia, Alessandro Antonelli, Luca Tondulli, Fabiana Conciatori, Chiara Bazzichetto, Giuseppe Verlato, Lorena Torroni, Michele Milella, Interleukin-8 as a potential prognostic biomarker in Renal Cell Carcinoma: A systematic review and Meta-Analysis, *The Oncologist*, **2025**; oyaf254, <https://doi.org/10.1093/oncolo/oyaf254>
- Rota M, **Torresan I**, Palmerio S, Tasselli E, Rossi A, Zivi A, Zacchi F. The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges. *Crit Rev Oncol Hematol*. **2025** Dec 3;217:105068. doi: 10.1016/j.critrevonc.2025.105068. Epub ahead of print. PMID: 41349781.
- Giunta EF, Schepisi G, Bleve S, Serra R, Brighi N, **Torresan I**, Tassinari E, Zanuccoli S, Lolli C. Neuroendocrine prostate cancer (NEPC) in focus: state of the art and future perspectives. *Discov Oncol*. **2026** Feb 14. doi: 10.1007/s12672-026-04482-7. Epub ahead of print. PMID: 41689691.

Abstract and Posters

- **Torresan I**, Mafficini A, Benini L, Borghesani M, Moscarda V, Trevisani E, Landoni L, De Robertis R, Luchini C, Milella M, Scarpa A, Cingarlini S. Exceptional response to Everolimus in a pancreatic NET G3: how NGS can help in treatment choice. Abstract 3891, ENETS Conference **2023**

- Trevisani E, Benini L, Borghesani M, Rossi A, **Torresan I**, Landoni L, De Robertis R, Luchini C, Milella M, Scarpa A, Cingarlini S. Precision Medicine in MiNEN and other rare pancreatic histologies: a case series from University Hospital of Verona. Abstract 3892 ENETS Conference **2023**
- Rossi A, Cingarlini S, Borghesani M, Moscarda V, **Torresan I**, Trevisani E, Landoni L, De Robertis R, Luchini C, Mafficini A, Milella M, Scarpa A. NGS data collection in high-grade (HG) pancreatic NENs at University Hospital of Verona. Abstract ENETS Conference **2023**, <https://onlinelibrary.wiley.com/doi/pdf/10.1111/jne.13265>, pag. 32.
- Viola Moscarda, Elena Trevisani, Anna Reni, Alice Rossi, **Irene Torresan**, Michele Borghesani, Silvia Nicolini, Lavinia Benini, Sara Cingarlini, Davide Melisi, Andrea Mafficini, Claudio Luchini, Luca Landoni, Aldo Scarpa, Michele Milella. Precision medicine applied to rare malignancies: a single-centre experience at University Hospital of Verona. DOI: 10.1200/JCO.2023.41.16_suppl.e16296 Journal of Clinical Oncology 41, no. 16_suppl (June 01, **2023**) e16296-e16296.
- **Torresan I**, Reni A, Trevisani E, Borghesani M, Rossi A, Nicolini S, Landoni L, Luchini C, Scarpa A, Milella M, Cingarlini S, Mafficini A. Pit and pitfalls of tumor mutational burden assessment in well-differentiated pancreatic neuroendocrine tumors: Two case reports from University of Verona. Abstract 4189 ENETS Conference **2024**
- Trevisani E, Reni A, **Torresan I**, Borghesani M, Nicolini S, Rossi A, Landoni L, Luchini C, Scarpa A, Milella M, Cingarlini S, Mafficini A. DNA damage repair genes alterations in pancreatic neuroendocrine tumor treated with Temozolomide. Abstract ENETS Conference **2024**, <https://onlinelibrary.wiley.com/doi/pdf/10.1111/jne.13383>, pag. 43
- Trevisani E, Reni A, **Torresan I**, Rossi A, Borghesani M, Nicolini S, Luchini C, Landoni L, Melisi D, Scarpa A, Milella M, Mafficini A, Cingarlini S. Molecular background conditioning by Temozolomide in neuroendocrine tumors. AACR; Cancer Res **2024**;84(6_Suppl): Abstract nr 3814. DOI:10.1158/1538-7445.AM2024-3814
- E. Trevisani, A. Mafficini, A. Reni, M. Borghesani, **I. Torresan**, A. Rossi, S. Nicolini, L. Landoni, C. Luchini, A. Scarpa, M. Milella, S. Cingarlini. Pit and pitfalls of tumor mutational burden (TMB) assessment in well-differentiated pancreatic neuroendocrine tumors: two case reports from University of Verona. <https://siica.it/wp-content/uploads/2024/07/ABSTRACT-BOOK.pdf>, pag. 20
- Zacchi F., Merler S., Torroni L., Zampiva I., Manduca S., Piacentini M., Pafumi S., Inzerilli N., Lorenzi C., **Irene T.**, Conciatori F., Bazzichetto C., Brunelli M., Calì A., Ugel S., Fantinel E., Verlato G., Milella M. Interleukin-8 as a potential prognostic biomarker in Renal Cell Carcinoma: A systematic review and Meta-Analysis. AIOM Congress **2024**, <https://journals.sagepub.com/doi/10.1177/03008916241277279>, Abstract D34, pag. 125
- Rossi A., Lawlor R.T., Cingarlini S., Auriemma A., Zecchetto C., Pilotto S., Pavarana M., Menis J., Sposito M., Trevisani E., **Torresan I.**, Insolda J., Luchini C., Mafficini A., Scarpa A., Milella M. Tissue-based Next Generation Sequencing (NGS) for patients with advanced solid tumors: the experience of Verona University Hospital. AIOM Congress **2024**, <https://journals.sagepub.com/doi/10.1177/03008916241277279>, Abstract H18 pag. 210
- **Torresan I.**, Sordo A., Lorenzi C., Merler S., Tasselli E., Pafumi S., Palmerio S., Durante E., Inzerilli N., Pellicciari M., Pastorelli D., Milella M., Zivi A., Zacchi F. Clinical Outcomes of Avelumab and Pembrolizumab in Advanced Urothelial Cancer: An Observational Multicenter Retro-Pro prospective Study on Patients Undergoing Treatment in Clinical Practice (AVePEm

Study). <https://doi.org/10.1016/j.ijotech.2024.100856>, ESMO Immuno-Oncology Congress 2024, Poster 113P

Speakers at conference

- IASGO 34th World Congress of International Association of Surgeons, Gastroenterologists and Oncologists. - Consortium molecular tumor board: panel discussion. Talk: Advanced High Grade Pancreatic Neuroendocrine Tumor with *RET* - *CCDC6* Fusion Treated with Selpercatinib - Verona, 9-12/09/2023

Courses

- December 16-17, 2025: ESMO Preceptorship on Prostate Cancer - Lugano (Switzerland)
- November 25-26, 2024: ESMO Advanced Course on ADC Development, Therapeutic Applications and Research: Thoracic and Genitourinary Cancers - Zurich (Switzerland)
- August 16-18, 2024: ESMO Academy 2024 - Zurich (Switzerland)
- September 14-15, 2023: NEN Preceptorship: la pratica clinica nelle neoplasie neuroendocrine – IEO Milano
- May 4-5, 2023: Spring Meeting ITAneXt – Loiano (Bologna)
- March 16-18, 2023: 35° Master Fondazione NIBIT in Immuno-Oncologia – CIO Siena
- September 22-23, 2022: NEN Preceptorship: la pratica clinica nelle neoplasie neuroendocrine – IEO Milano

Membership

- AIOM membership since 2024
- AACR membership since 2024 (ID: 1398547)
- ESMO membership since 2022 (ID: 539353)

Languages spoken

- Italian: mother tongue
- English: B2